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receptor. We sought to determine whether inhibition of SPARC activity using anti-SPARC peptide could
inhibit laser-induced CNV by promoting binding of VEGF-A to FLT-1. We created anti-SPARC L-peptide
and retro-inverso anti-SPARC D-peptide. Anti-SPARC peptides or PBS were injected intravitreally 1 day
before or after laser induction. Intravitreal injection of anti-SPARC L-peptide 1 day before laser induction
promotes FLT-1 phosphorylation and inhibited laser-induced CNV and anti-SPARC D-peptide had no
effect. Injection 1 day after laser injury did not affect size of laser-induced CNV. Inhibition of SPARC activ-
ity could be complementary to existing anti-CNV therapy.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Neovascularization, the abnormal growth of new blood vessels,
plays an important role in many diseases, including cancer and
blindness (Bellner et al., 2008; Epstein, Stulting, Hendricks, &Harris,
1987; Folkman, 1990). In patients with age-related macular degen-
eration (AMD) choroidal neovascularization (CNV) is a principal
cause of blindness (Smith et al., 2001). CNV grows from the choroid
into the subretinal space. These blood vessels may bleed into the
subretinal space resulting in edema and tissue damage. Vascular
endothelial growth factor (VEGF)hasbeen found tobeapotent stim-
ulator of CNV (Amin, Puklin, & Frank, 1994; Ng & Adamis, 2005).
FLT-1 (also referred as VEGF receptor-1) and KDR (also referred as
VEGF receptor-2) are the principal VEGF receptors and are critically
involved in neovascularization and angiogenesis (de Vries et al.,
1992; Matsumoto et al., 2005; Shibuya, 1995, 2006; Shibuya &
Claesson-Welsh, 2006). Generally, activation of KDR by VEGF
promotes angiogenesis. On the other hand, FLT-1 signaling has been
reported to both promote (Carmeliet et al., 2001; Hiratsuka et al.,
2001) and suppress angiogenesis (Bussolati et al., 2001; Kearney
et al., 2002), depending on the tissue and context. In addition, due
to alternative splicing, the FLT-1 gene produces membrane-bound
FLT-1 and soluble FLT-1 isoforms. Soluble FLT-1 has a partial extra-
cellular domain of membrane FLT-1 and a unique C-terminal
peptide. Soluble FLT-1 binds VEGF-A as an extracellular antagonist
and blocks its signaling. It is known that soluble FLT-1 is vital toll rights reserved.
Uehara).corneal avascularity (Ambati et al., 2006). While VEGF is critical to
angiogenesis, VEGF overexpression alone does not induce CNV in
mice (Oshima et al., 2004). This indicates other cellular or extracel-
lular components may play key roles in the development of CNV.
In this study, we focused on the role of SPARC (secreted protein,
acidic and rich in cysteine; also known as BM-40 and osteonectin)
in laser-induced CNV, a well-established model for age-related
macular degeneration. SPARC belongs to the matricellular family
that mediates cell–matrix interactions, which affect biological
functions including proliferation, survival, adhesion and migration
(Bornstein & Sage, 2002). SPARC binds to VEGF and inhibits tyro-
sine phosphorylation of FLT-1 but not KDR (Kupprion, Motamed,
& Sage, 1998). Nozaki et al. demonstrated reduced SPARC tempo-
rarily after laser injury in the choroid, creating a window of per-
missibility for VEGF binding to FLT-1. FLT-1 activation inhibits
signal transduction of KDR through SHP-1 and can decrease la-
ser-induced CNV volume (Nozaki et al., 2006). Based on these ear-
lier studies we hypothesized inhibition of SPARC activity could
reduce or prevent laser-induced CNV. Based on this hypothesis
we created anti-SPARC peptides to bind SPARC by phage-screening
and examined the effect of anti-SPARC peptides on a laser-induced
CNV model.2. Methods
2.1. Phage-screening for anti-SPARC peptide
The Ph.D.™ Phage Display Peptide Library Kit (New England
Biolabs, Ipswich, USA) was used for in vitro biopanning procedures.
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tide 7-mers fused to a minor coat protein, pIII, of the ﬁlamentous
coliphage M13. Phage selection in vitro was performed according
to the manufacture’s protocol. SPARC recombinant proteins were
coated on 96-well plates in 0.1 M NaHCO3 coating buffer and incu-
bated overnight at 4 C. The next day the plates were washed with
0.1% Tween-20 in TBS (TBST), followed by blocking in 3% BSA for
1 h. In the ﬁrst round of biopanning, 2  1011 phage (100 equiva-
lents of original library) were added to each well with 0.1% bovine
serum albumin (BSA) and incubated for 1 h at room temperature.
The plates were then washed 10 times with TBST. After washing,
100 ll of 0.2 M Glycine–HCl (pH 2.2) and 1 mg/ml BSA were added
to the wells to elute recombinant protein bound phage. One micro-
liter of eluted phage was tittered on LB/IPTG/Xgal plates and blue
plaques were counted and phage titer was determined. The
remaining phage was ampliﬁed using ER2738 E. Coli in LB-Tet
according to the manufacture’s instructions. For the following
steps 2  1011 pfu plaques were use. We performed four cycles of
binding and ampliﬁcation on the previously eluted and ampliﬁed
phage to enrich the pool in favor of binding sequences.
2.2. Surface plasmon resonance
Interaction between anti-SPARC L- or D-peptide and SPARC was
determined by Biacore 2000 (GE Healthcare/Biacore, Uppsala, Swe-
den). SPARC from PYS-2 cell (sigma) was immobilized using stan-
dard amine-coupling chemistry to a density of 2100 resonance
units (RU). As a control, we also immobilized 2100 RU carbonic
anhydrase. The peptides were tested in duplicate in a two-fold
dilution series for binding to the protein surfaces. Fitting the re-
sponses to a simple binding isotherm yielded the afﬁnities.
2.3. Intravitreal peptide injection
Wild-type C57/BL6 mice were purchased from Jackson Labora-
tory. Mice (6–8 weeks old) were anesthetized by intraperitoneal
injection of Ketaset (50 mg/kg; Wyeth, Fort Dodge, USA) and xyla-
zine (Tranqui Ved, 10 mg/kg; VEDCO, St. Joseph, USA). Anti-SPARC
L-peptide (20 ng or 2 lg), anti-SPARC D-peptide (20 ng or 2 lg), or
PBS, as a control, was injected into the vitreous cavity in a total vol-
ume of 1 ll with 33-gauge micro syringe (Hamilton Company,
Reno, USA).
2.4. Laser induced choroidal neovascularization
Laser photocoagulation (532 nm, 100 mV, 100 ms, 50 lm; NI-
DEK MC-4000) was performed on both eyes (2–5 spots per eye)
as described (Sakurai, Anand, Ambati, van Rooijen, & Ambati,
2003; Sakurai et al., 2003). After enucleating the eyes, sclera/cho-
roid/RPE complex were ﬁxed in 4% paraformaldehyde for 2 h at
4 C. After blocking in 5% FBS/PBS with 0.02% tritonX-100 and
2 mM MgCl2, samples were stained with 5 lg/ml Alexa488 conju-
gated isolectin GS-IB4 (Invitrogen Corporation, Carlsbad, USA)
overnight. After washing the samples were ﬂat mounted on glass
slides. CNV volume was measured by scanning laser confocal
microscopy (Olympus America Inc., Center Valley, USA).
2.5. Immunoprecipitation and Western Blot
After euthanizing the mice, RPE/choroid complex was separated
from sclera under a stereomicroscope and placed in 200 ll of RIPA
buffer (Sigma–Aldrich, St. Louis, USA) containing protease inhibitor
cocktail (Roche Diagnostics Corporation, Indianapolis, USA) and
Halt™ phosphatase inhibitor (Fisher Scientiﬁc, Pittsburg, USA).
After homogenization with a sonic dismembrator (Fisher Scientiﬁc,
Pittsburg, USA), 150 ll samples were subjected to immunoprecip-itation for FLT-1 or KDR. For immunoprecipitation we used protein
G or A coated magnetic beads (Invitrogen Corporation, Carlsbad,
USA) and mouse anti-FLT-1 antibody or rabbit anti-KDR antibody
(Abcam Inc., Cambridge, USA) following manufacture’s instruc-
tions. The proteins were eluted with Laemmli buffer for 10 min
at 70 C and resolved by SDS–PAGE (8%) under reducing conditions.
The protein was transferred to a nitrocellulose membrane and
incubated for 1 h with blocking buffer (3% BSA and 0.05% Tween-
20 in TBS) then incubated with anti-phospho-FLT-1(Tyr1213) anti-
body (1:1000, Millipore, Billerica, USA) or anti-tyrosine phosphor-
ylation antibody in blocking buffer for 1 h at room temperature.
The membrane was washed once in TBST (0.05% Tween-20/TBS)
and twice in TBS. Finally, the membrane was incubated with the
appropriate secondary HRP-linked antibody in blocking buffer for
30 min at room temperature. After washing once with TBST and
thrice with TBS, the bands were illuminated by an ECL-PLUS Wes-
tern Blot detection kit (Amersham Biosciences, Pittsburg, USA) and
detected by FOTO/Analyst Electronic Imaging Systems (Fotodyne
Inc., Hartland, USA).2.6. Statistics
Data are shown as mean ± sem or sd. P values were calculated
using student’s t-test.3. Results
3.1. Generation of anti-SPARC peptide
SPARC is expressed in retinal pigment epithelium (RPE) (Hiscott
et al., 2002). In addition, we detected SPARC in the cornea, lens and
retina by immunohistochemistry, although the signal intensities
less than RPE (data not shown). Laser-induced CNV occurs from
the choroid to the retina through the RPE. The RPE is thought to
play a key role in early and late stage AMD (Schmitz-Valckenberg,
Fleckenstein, Scholl, & Holz, 2009). We had previously determined
the probable mode of VEGF–SPARC binding via computational
molecular docking (Chandrasekaran, Ambati, Ambati, & Taylor,
2007) as well as the relevance of that interaction in gating VEGF
angiogenic vs. anti-angiogenic effects in a laser-induced CNV mod-
el (Nozaki et al., 2006). We therefore hypothesized that inhibiting
SPARC binding of VEGF would inhibit laser-induced CNV.
To inhibit SPARC activity we employed a small peptide, as we
hypothesized small molecules would enter the RPE more efﬁ-
ciently and induce less inﬂammation than antibodies. In addition
we thought a small peptide would limit only SPARC activity to
VEGF effectively. To create the peptide blocking SPARC activity
we performed phage-screening against SPARC and obtained the
L-peptide sequence SMPTYNK. There were two small regions of
VEGF predicted to have signiﬁcant protein–protein interactions
with SPARC (one around residue 200, and another around 260–
270; amino acid number according to Genbank ﬁle AAH65522)
(Chandrasekaran et al., 2007). We compared L-peptide SMPTYNK
with these regions of VEGF and found two possible matches
(Fig. 1). Results from X-ray crystallographic analysis and mutagen-
esis studies concluded FMDVYQR is a helix near the binding site of
VEGF to FLT-1 and KDR (Keyt, Berleau, et al., 1996; Keyt, Nguyen,
et al., 1996; Wiesmann et al., 1997). From the 3-D docking model
of VEGF-SPARC binding (Chandrasekaran et al., 2007) Met (M)
and Tyr (Y) residues project on the same side of the helix forming
an MXXY motif, a feature of SMPTYNK. We believe this part of
VEGF-A binds to SPARC and inhibits SPARC activity. Based on these
considerations we selected L-KFMDVYNR as anti-SPARC L-peptide.
In addition to anti-SPARC L-peptide, we synthesized anti-SPARC D-
peptide (retro-inverso peptide, D-RNYVDMFK), sequenced based
Fig. 1. Potential matches of phage display derived L-peptide SMPTYNK to the VEGF protein sequence. Underlined residues in VEGF are predicted to be sites of interaction with
SPARC (Table 1 and the reference Chandrasekaran et al. (2007)) by H-bonding or predicted hydrophobic interactions (e.g. FM near N-terminus shown). Exact matches are
shown in bold, similarities in italics. Note that NK in the peptide is functionally similar to QR in VEGF. The partial VEGF-A sequence shown is numbered according to Genbank
ﬁle AAH65522.
Table 1
Interaction between anti-SPARC peptides and SPARC protein measured by surface
plasmon resonance.
Dissociation constant (KD)
Anti-SPARC L-peptide 2.0 (mM)
Anti-SPARC D-peptide 1.6 (mM)
676 H. Uehara et al. / Vision Research 50 (2010) 674–679on anti-SPARC L-peptide. To conﬁrm if anti-SPARC L-peptide and D-
peptide bind to SPARC we measured the interaction by surface
plasmon resonance (SPR; Table). We found the interaction be-
tween SPARC and anti-SPARC L-peptide or D-peptide exists
although the interactions were weak.3.2. Anti-SPARC L-peptide injection before laser photocoagulation
inhibits laser CNV volume
To determine if anti-SPARC peptide decreases laser CNV volume
in mice we injected anti-SPARC L-peptide or D-peptide at 20 ng and
2 lg into the intravitreous cavity. One day after the injections we
performed 2–5 spots of laser photocoagulation in each eye. After
10 days the volumes of laser CNV were measured by confocal
microscopy. Fig. 2 represents the laser-induced CNV of PBS (a, b),Fig. 2. Anti-SPARC L-peptide injection before laser inhibits CNV. One day before laser inj
Representative ﬂuorescence images are shown (a–f). PBS injection as a control (a, b). An
20 ng (e) and 2 lg (f). Scale bar: 200 lm. Anti-SPARC L-peptide (g) reduced laser CNV vo
factor by student t-test. p < 0.01, p < 0.001. Error bar: sem.anti-SPARC L-peptide 20 ng (c), 2 lg (d), and anti-SPARC D-peptide
20 ng (e), and 2 lg (f) injections. The anti-SPARC L-peptide injec-
tions decreased laser CNV volume in a dose-dependent manner
compared with PBS injections, however anti-SPARC D-peptide did
not affect the laser-induced CNV volume (Fig. 2g). The sample
number of each group was 10–15 laser-CNV spots.3.3. Anti-SPARC L-peptide injections after laser photocoagulation do
not affect laser CNV volume
We injected anti-SPARC L- or D-peptide at 20 ng or 2 lg after
1 day of laser photocoagulation. After 10 days the volumes of laser
CNV were measured (Fig. 3). Unlike anti-SPARC L-peptide injection
before laser photocoagulation, we could not detect a signiﬁcant ef-
fect. The sample number of each group was 10–15 laser-CNV spots.3.4. Anti-SPARC L-peptide increased phosphorylation of FLT-1 and
decreased phosphorylation of KDR after 1 day of laser
photocoagulation in vivo
Because it was reported that SPARC sequesters phosphorylation
of FLT-1 by VEGF (Kupprion et al., 1998), we investigated whetherury, PBS, anti-SPARC L-peptide or D-peptide was injected into the intravitreal cavity.
ti-SPARC L-peptide injection, 20 ng (c) and 2 lg (d). Anti-SPARC L-peptide injection,
lume, while anti-SPARC D-peptide showed no reduction compared with PBS. P: risk
Fig. 3. Anti-SPARC peptide injection after laser injury does not affect CNV. One day
after laser injury, PBS, anti-SPARC L-peptide and D-peptide were injected intravit-
really. Signiﬁcant differences were not found. Error bar: sem.
Fig. 4. FLTphosphorylation is increased, butKDRphosphorylation isdecreasedbyanti-SPA
cavity 1 day before laser injury. One or twodays after laser photocoagulation, the RPE/choro
Blot for phosphorylation of each protein were performed. (a) FLT-1, (b) KDR. Each ﬁgure
examined in the same sample. Densitometric ratio of phosphoFLT-1 to FLT and phosphoKD
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and eventually decrease phosphorylation of FLT-1. One day after
anti-SPARC L-peptide, D-peptide or PBS injection we performed la-
ser photocoagulation. One to two days later RPE/choroid was care-
fully dissected from sclera and we examined phosphorylation of
FLT-1 and KDR by Western Blot (Fig. 4). Western Blot showed
anti-SPARC L-peptide increased phosphorylation of FLT-1 after
1 day of laser photocoagulation compared with PBS or anti-SPARC
D-peptide injection. Two days after laser photocoagulation there
were no signiﬁcant differences in phosphorylation of FLT-1. Con-
versely, phosphorylation of KDR was decreased 1 day after but
not 2 days after laser photocoagulation.4. Discussion
VEGF, as a potent inducer of CNV, has been studied and its inhi-
bition by anti-VEGF antibody (ranibizumab) has shown improve-
ment of AMD patients’ vision (Chang et al., 2007; Rosenfeld et al.,
2006). Despite this discovery, its application has been limited to
advanced stages. We believe treatment at earlier stages will be
necessary to decrease CNV growth or prevent CNV. In addition,
clinical trials of pegaptanib in AMD patients showed an inverse
therapeutic dose response (Gragoudas, Adamis, Cunningham, Fein-
sod, & Guyer, 2004). This indicates over-inhibition of VEGF may
lead to an adverse effect and we hypothesized that the treatment
of other targets related to VEGF may be helpful for AMD patients.
In addition to VEGF regulation, several other growth factors are
affected by SPARC. For example, the stimulation of platelet-derived
growth factor induced proliferation of human arterial vascularRC L-peptide. PBS, anti-SPARC L-peptideor D-peptidewere injected to the intravitreous
idwas separated fromsclera and immunoprecipitation for FLT-1 orKDR andWestern
is representation of three individual experiments. As a control, FLT-1 or KDR was
R to KDR are shown as PBS treated one is 1.0. Error is sd. P: risk factor by student t-test.
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et al., 2002). Transforming growth factor b is also regulated by
SPARC (Francki et al., 2004).
In this study we focused on SPARC activity as it relates to VEGF.
We designed a small peptide to inhibit SPARC by phage-screening
and previous computational analysis predictions (Chandrasekaran
et al., 2007). Intravitreal injection of L-anti-SPARC peptide 1 day
before laser photocoagulation prevented laser-induced CNV
growth. However, we could not ﬁnd a signiﬁcant difference in la-
ser-induced CNV when we injected anti-SPARC peptide after laser
injury. This may be due to two reasons. (1) Previous studies re-
ported that 1 day after laser photocoagulation SPARC decreased
in RPE/choroid temporarily, but recovered the next day (Nozaki
et al., 2006). Hence, injection of anti-SPARC L-peptide after laser in-
jury may not have a target as SPARC had already declined. (2) This
may indicate SPARC regulation is operative in the initial phases of
laser injury and determines the fate of cells in CNV through FLT-1
and KDR signaling. This concept is supported byWestern Blot anal-
ysis of phosphorylation of FLT-1 and KDR (Fig. 4). In eyes injected
with anti-SPARC L-peptide 1 day before laser injury, phosphoryla-
tion of FLT-1 increased. Conversely, KDR phosphorylation de-
creased 1 day after laser photocoagulation. We could not detect
differences in phosphorylation of FLT-1 and KDR in eyes treated
2 days after laser photocoagulation. Alternatively, it is possible that
SPARC function may change in response to injury (Arnold &
Brekken, 2009).
Although surface plasmon resonance showed low interaction
between SPARC and anti-SPARC L-peptide, anti-SPARC L-peptide
injection 1 day before laser photocoagulation reduced laser-in-
duced CNV volume. It is possible that our dose of anti-SPARC L-pep-
tide may overcome low binding afﬁnity, further underlining the
importance of SPARC at the initial stages of laser-induced CNV.
We successfully prevented laser-induced CNV using anti-SPARC
L-peptide, but anti-SPARC D-peptide, which interacts with SPARC as
much as anti-SPARC L-peptide did not inhibit CNV compared with
PBS injection 1 day before or after laser photocoagulation. It is un-
clear why the D-peptide did not exert an inhibitory effect; one pos-
sibility is that there may be L-peptide speciﬁc transporters which
enable transport of intravitreal peptides across the retina to sites
of injury. Alternatively, there may be subtle steric interference
points in the in vivo extracellular matrix blocking the anti-SPARC
D-peptide activity. Fig. 4 shows that anti-SPARC L-peptide, but
not anti-SPARC D-peptide, promoted phosphorylation of FLT-1
and decreased phosphorylation of KDR. This suggests that anti-
SPARC D-peptide may bind to SPARC but not inhibit SPARC–VEGF
interactions in vivo.
The clinical relevance of ﬁnding anti-SPARC intervention to be
most effective immediately prior to laser injury in a murine model
will depend on progress in assessing SPARC levels in macular
degeneration patients. Patients with normal or above-normal
SPARC levels may beneﬁt from a combination of anti-SPARC plus
anti-VEGF therapy.
In summary, we have shown that inhibition of SPARC by anti-
SPARC L-peptide prior to laser photocoagulation reduces the vol-
ume of laser-induced CNV and that this is associated with in-
creased phosphorylation of FLT-1 and decreased phosphorylation
of KDR. Our results also conﬁrm that SPARC plays a key role in
the initial stages of laser-induced CNV. This may lay the foundation
for anti-SPARC therapy to complement existing treatments for
AMD.
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